Y-Intercept (HK)
ACRS icon

Y-Intercept (HK)’s Aclaris Therapeutics ACRS Stock Holding History

Y-Intercept (HK)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$82.9K Buy
+15,759
New +$90K ﹤0.01% 1514
2024
Q3 		– Sell
-114,806
Closed -$126K – 1244
2024
Q2 		$126K Buy
+114,806
New +$135K 0.01% 1234

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Three Bridge Wealth Advisors
Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Y-Intercept (HK)'s ACRS Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 15,759 shares worth $82.9K. The stake represents ﹤0.01% of the portfolio and ranks #1514 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in ACRS as recently as Q2 2024.

Y-Intercept (HK) first reported a position in ACRS in Q2 2024 and has held it in 2 quarters since. The position peaked at $126K in Q2 2024. 61 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Y-Intercept (HK) held 15,759 shares of Aclaris Therapeutics worth $82.9K as of Q3 2026.
  • Aclaris Therapeutics was a new Y-Intercept (HK) position in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1514 holding.
  • Y-Intercept (HK) first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • Y-Intercept (HK)'s Aclaris Therapeutics position peaked at $126K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.